Table 1.

Patient characteristics

	N	%	Median (IQR)
Patients	333
Death	114
Age, years			71 (62–77)
<65	104	31.2
65–74	109	32.7
≥75	120	36.0
Female	210	63.1
RA and PMR	52	15.6
Psoriatic arthritis and spondylarthritis	0	0.0
Primary vasculitis syndrome	116	34.8
Systemic lupus erythematosus	49	14.7
Inflammatory myositis	60	18.0
Systemic sclerosis	13	3.9
Others	43	12.9
Concomitant ILD	122	36.6
Admission to an advanced treatment hospital	94	28.2
Bronchoscopy	36	10.8
Intensive care management	37	11.1
Ventilator use	83	24.9
Length of hospital stay after starting PCP treatment, days			33 (4–37)
Glucocorticoid therapy
Concomitant glucocorticoid use	322	96.7
Glucocorticoid pulse therapy	103	30.9
Antibiotics for PCP
ST monotherapy	214	64.3
Others	119	35.7
PTM group	80	24.0
PTM monotherapy	32	8.4
ST → PTM	48	14.4
ATO group	29	8.7
ATO monotherapy	9	2.7
ST → ATO	20	6.0
Other combinations	10	3.0
Adjunctive therapy
Gamma-globulin	31	9.3
Albumin	40	12.0
Empiric antibiotic therapy	245	73.6
Antifungal drugs	110	33.0
Anticytomegalovirus drugs	56	16.8

ATO, atovaquone; ILD, interstitial lung disease; PCP, pneumocystis pneumonia; PMR, polymyalgia rheumatica; PTM, pentamidine; RA, rheumatoid arthritis; ST, sulfamethoxazole/trimethoprim.